Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia

OBJECTIVES:

- To perform high-resolution, genome-wide profiling of DNA copy number alterations and
loss-of-heterozygosity in samples from adult patients with acute lymphoblastic leukemia
(ALL) obtained at diagnosis.

- To perform candidate gene resequencing of diagnostic ALL samples.

- To examine correlation of genetic alterations with outcome.

- To examine the correlation between microarray multi-gene and multi-exon expression
signatures with specific alterations and outcome.

- To understand genetic events that contribute to the formation, development, and relapse
of adult ALL by integrating the copy number and sequence alterations with the multi-gene
signatures, and by comparing these data with data already generated in pediatric ALL.

OUTLINE: Diagnostic, complete remission, and germ-line specimens are analyzed for DNA
profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and
fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by
the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from
pediatric patients.

Inclusion:

• Diagnostic and germ-line specimens from patients with acute lymphoblastic leukemia (ALL)
treated on protocols CALGB 9511, CALGB-19802, CALGB-10001, CALGB-10102, and CALGB-10403 and
who have been registered on the companion study CALGB-9665 (The CALGB Leukemia Tissue Bank)